RxDoctor Payments DataLook up a doctor →

Hector Robles, MD

Internal Medicine · Lafayette, LANPI 1548367147

Payments from drug & device makers

$19,012in general payments, 2019–2025

Across 1,074 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • AbbVie$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • Bayer$989
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca111$2,292
Novo Nordisk118$1,879
AbbVie(2 entities)107$1,679
Amgen97$1,422
Lilly USA, LLC83$1,212
Bayer34$989
Johnson & Johnson61$802
Pfizer53$734
Boehringer Ingelheim34$667
Novartis28$531
Sanofi-aventis U.S. LLC31$484
Amarin Pharma, Inc.22$397
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC21$347
Mylan Specialty L.p.17$321
Axsome Therapeutics, Inc.5$311
Idorsia Pharmaceuticals US Inc9$303
GSK16$275
Biogen11$274
Astellas Pharma US Inc18$266
Coloplast2$263
Teva Pharmaceuticals USA, Inc.15$262
Antares Pharma, Inc.9$227
Kowa Pharmaceuticals America, Inc.14$219
Supernus Pharmaceuticals, Inc.25$215
Ardelyx, Inc.15$207
Esperion Therapeutics, Inc.9$195
Insmed, Inc.7$193
Exact Sciences10$187
Avanir Pharmaceuticals, Inc.4$164
Abbott7$149
Daiichi Sankyo Inc.8$135
Teleflex LLC1$132
Takeda Pharmaceuticals U.S.A., Inc.8$127
Phathom Pharmaceuticals, Inc.5$117
E.r. Squibb & Sons, L.L.C.6$91
Gilead5$85
Corcept Therapeutics3$66
Mannkind Corporation1$59
Tolmar, Inc.3$54
Arbor Pharmaceuticals, Inc.4$54
Otsuka America Pharmaceutical, Inc.3$50
Zyla Life Sciences, Inc.2$45
Alnylam Pharmaceuticals Inc.2$43
Merck3$43
Shield Therapeutics Inc2$40
Currax Pharmaceuticals LLC3$39
Eisai Inc.2$36
Sunovion Pharmaceuticals Inc.4$32
Nevro Corp.1$31
Jazz Pharmaceuticals Inc.2$29
Sumitomo Pharma America, Inc.1$26
Optinose US, Inc.1$23
Lexicon Pharmaceuticals, Inc.1$21
Mallinckrodt Hospital Products Inc.1$21
Insulet Corporation1$20
Alfasigma USA, Inc.1$18
Medtronic1$18
Shire North American Group Inc1$18
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Dexcom, Inc.1$16

How this compares

$19,012 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana →

Medicare billing

Part B allowed, 2024
$233,770
Medicare patients
271
Services billed
2,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Lafayette

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →